

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

GRANT OF SHARE OPTIONS

The Board announces that on December 20, 2021, a total of 178,000 Share Options were granted to certain eligible persons pursuant to the 2020 Equity Incentive Plan to subscribe for a total of 178,000 Shares. According to Rule 17.06A of the Listing Rules, details of the grant of Share Options are set out as follows:

1. Date of grant December 20, 2021
2. Number of grantees 5
3. Exercise price of the Share Options granted HK\$10.288. The exercise price of HK\$10.288 per Share represents the highest of (i) the closing price of HK\$9.660 per Share as stated in the daily quotation sheet issued by the Stock Exchange on the date of the grant; (ii) the average closing price of HK\$10.288 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five trading days immediately preceding the date of grant; and (iii) the nominal value of the Share, which is US\$0.0001.
4. Total number of the new Share Options granted 178,000
5. Validity period of the Share Options 10 years from the date of grant, i.e. from December 20, 2021 to December 19, 2031 (both days inclusive)

None of the grantees is a Director, chief executive or substantial shareholder of the Company or an associate of any of them. The grant of the Share Options to the above grantees is not subject to approval by shareholders of the Company under Rule 17.04(1) of the Listing Rules.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the following meanings:

“2020 Equity Incentive Plan”	the 2020 equity incentive plan adopted by the Company on August 18, 2020
“associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Board”	the board of Directors
“Company”	Antengene Corporation Limited (德琪醫藥有限公司), an exempted company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board of the Stock Exchange
“Director(s)”	director(s) of the Company
“HK\$”	Hong Kong dollar(s), the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended from time to time
“Share(s)”	ordinary share(s) in the share capital of the Company with a par value of US\$0.0001 each
“Share Option(s)”	the share option(s) to be granted pursuant to the terms and conditions of the 2020 Equity Incentive Plan
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“substantial shareholder(s)”	has the meaning ascribed thereto under the Listing Rules
“US\$”	United States dollars, the lawful currency of the United States of America

By Order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, December 20, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin, Mr. Donald A. Lung and Dr. Kevin P. Lynch as executive directors; Dr. Kan Chen and Mr. Yilun Liu as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.